RU2445975C2 - Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента - Google Patents

Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента Download PDF

Info

Publication number
RU2445975C2
RU2445975C2 RU2008139118/15A RU2008139118A RU2445975C2 RU 2445975 C2 RU2445975 C2 RU 2445975C2 RU 2008139118/15 A RU2008139118/15 A RU 2008139118/15A RU 2008139118 A RU2008139118 A RU 2008139118A RU 2445975 C2 RU2445975 C2 RU 2445975C2
Authority
RU
Russia
Prior art keywords
complement
specified
inhibits
drug
allograft
Prior art date
Application number
RU2008139118/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2008139118A (ru
Inventor
Расселл П. РОТЕР (US)
Расселл П. Ротер
Хао ВАН (CA)
Хао ВАН
Чжень ЧЖУН (CA)
Чжень ЧЖУН
Original Assignee
Алексион Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2445975(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Алексион Фармасьютикалз, Инк. filed Critical Алексион Фармасьютикалз, Инк.
Publication of RU2008139118A publication Critical patent/RU2008139118A/ru
Application granted granted Critical
Publication of RU2445975C2 publication Critical patent/RU2445975C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2008139118/15A 2006-03-02 2007-03-02 Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента RU2445975C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77885906P 2006-03-02 2006-03-02
US60/778,859 2006-03-02

Publications (2)

Publication Number Publication Date
RU2008139118A RU2008139118A (ru) 2010-04-10
RU2445975C2 true RU2445975C2 (ru) 2012-03-27

Family

ID=38475394

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008139118/15A RU2445975C2 (ru) 2006-03-02 2007-03-02 Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента

Country Status (21)

Country Link
US (1) US20100135992A1 (https=)
EP (2) EP2918269A1 (https=)
JP (2) JP5722524B2 (https=)
KR (2) KR101527225B1 (https=)
CN (1) CN101437501B (https=)
AU (1) AU2007224250B2 (https=)
BR (1) BRPI0708424A2 (https=)
CA (1) CA2644020C (https=)
DK (1) DK1988882T3 (https=)
ES (1) ES2530637T3 (https=)
HR (1) HRP20150182T1 (https=)
IL (1) IL193623A0 (https=)
MX (1) MX2008011054A (https=)
NZ (1) NZ570802A (https=)
PL (1) PL1988882T3 (https=)
PT (1) PT1988882E (https=)
RS (1) RS53864B1 (https=)
RU (1) RU2445975C2 (https=)
SG (1) SG171578A1 (https=)
SI (1) SI1988882T1 (https=)
WO (1) WO2007103134A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742606C2 (ru) * 2015-12-18 2021-02-09 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11597760B2 (en) 2014-12-19 2023-03-07 Chugai Seiyaku Kabushiki Kaisha Method of detecting the presence of complement C5
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US12169205B2 (en) 2014-12-19 2024-12-17 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US12595299B2 (en) 2015-02-05 2026-04-07 Chugai Seiyaku Kabushiki Kaisha FC variants

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
CA2662480C (en) 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
LT2894165T (lt) * 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
US20130028897A1 (en) * 2009-04-27 2013-01-31 Ali Naji Methods for reducing the level of alloantibodies in a subject
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
JP5871798B2 (ja) * 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CN101621801B (zh) * 2009-08-11 2012-11-28 华为终端有限公司 无线局域网的认证方法、系统及服务器、终端
CN110124039A (zh) 2011-05-16 2019-08-16 建新公司 使用甲氨蝶呤诱导免疫耐受性
CN102585016B (zh) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
CN103232542B (zh) * 2013-02-01 2015-05-13 殷勇 一种双靶标嵌合蛋白
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
US20160184391A1 (en) * 2013-08-16 2016-06-30 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
US20180311345A1 (en) * 2015-10-30 2018-11-01 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
EP3463459A1 (en) * 2016-06-07 2019-04-10 Novartis AG Tesidolumab for use in the treatment of transplant rejection
CN109310760A (zh) * 2016-06-07 2019-02-05 诺华股份有限公司 抗c5抗体给药方案
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
SI3658184T1 (sl) 2017-07-27 2024-01-31 Alexion Pharmaceuticals, Inc., Formulacije z visoko koncentracijo protiteles proti-C5
CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
CN112996561A (zh) 2018-10-30 2021-06-18 亚力兄制药公司 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020231882A2 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
CA3152922A1 (en) 2019-10-12 2021-04-15 Michael Peel Treatment and prevention of nephrotoxin-induced kidney injuries
EP4585223A3 (en) * 2020-01-15 2025-07-30 The Regents of the University of California Transplanted cell protection via inhibition of polymorphonuclear cells
US12465629B2 (en) 2020-04-15 2025-11-11 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2169009C2 (ru) * 1994-04-25 2001-06-20 Трастиз Оф Дартмут Колледж Способы индуцирования т-клеточной толерантности к тканевому или органному трансплантату
RU2174405C2 (ru) * 1997-10-23 2001-10-10 Сэнгстат Медикал Корпорейшн Композиция циклоспорина для перорального введения (варианты) и способ достижения иммуносупрессии в организме реципиента

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
CA2319448A1 (en) 1998-02-04 1999-08-12 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allotransplantation
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
WO2000027421A2 (en) 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US6192891B1 (en) * 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
WO2001057184A2 (en) * 2000-02-01 2001-08-09 Vanderbilt University Use of platelet activity modulators for inhibiting complement activation
AU2001296594A1 (en) * 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
BRPI0211953B8 (pt) * 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
AU2003209308A1 (en) * 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
US20040146503A1 (en) * 2002-08-28 2004-07-29 Tesi Raymond J. Methods and compositions for inducing stable immune tolerance
WO2005025509A2 (en) * 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
ES2528362T3 (es) * 2004-05-14 2015-02-09 Alexion Pharmaceuticals, Inc. Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento
EP1781267A4 (en) * 2004-05-17 2009-03-11 Combinatorx Inc METHOD AND REAGENTS FOR THE TREATMENT OF INFAMOUS DISEASES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2169009C2 (ru) * 1994-04-25 2001-06-20 Трастиз Оф Дартмут Колледж Способы индуцирования т-клеточной толерантности к тканевому или органному трансплантату
RU2174405C2 (ru) * 1997-10-23 2001-10-10 Сэнгстат Медикал Корпорейшн Композиция циклоспорина для перорального введения (варианты) и способ достижения иммуносупрессии в организме реципиента

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIN WP et al. Synergistic tolerance induced by LF 15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells// Transplantation. 2003 Apr 27; 75(8):1160-5. реферат, онлайн [Найдено в Интернет на www.pubmed.com 24.12.2010], РМID: 12717196 [PubMed - indexed for MEDLINE]. ZHOU D et al. LF 15-0195, a novel immunosuppressive agent prevents rejection and induces operational tolerance in a mouse cardiac allograft model // Transplantation. 2003 Aug 27; 76(4):644-50 реферат, онлайн [Найдено в Интернет на www.pubmed.com 24.12.2010], PMID: 12973102 [PubMed - indexed for MEDLINE]. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US12473375B2 (en) 2006-03-31 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US12116414B2 (en) 2007-09-26 2024-10-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12122840B2 (en) 2007-09-26 2024-10-22 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11597760B2 (en) 2014-12-19 2023-03-07 Chugai Seiyaku Kabushiki Kaisha Method of detecting the presence of complement C5
US12169205B2 (en) 2014-12-19 2024-12-17 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US12595299B2 (en) 2015-02-05 2026-04-07 Chugai Seiyaku Kabushiki Kaisha FC variants
RU2742606C2 (ru) * 2015-12-18 2021-02-09 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US12516115B2 (en) 2016-08-05 2026-01-06 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases

Also Published As

Publication number Publication date
RS53864B1 (sr) 2015-08-31
CN101437501A (zh) 2009-05-20
SI1988882T1 (sl) 2015-07-31
CA2644020C (en) 2016-05-10
PT1988882E (pt) 2015-02-17
BRPI0708424A2 (pt) 2011-05-31
KR20080098543A (ko) 2008-11-10
PL1988882T3 (pl) 2015-04-30
ES2530637T3 (es) 2015-03-04
EP1988882B1 (en) 2014-12-17
CA2644020A1 (en) 2007-09-13
MX2008011054A (es) 2009-03-03
WO2007103134A2 (en) 2007-09-13
SG171578A1 (en) 2011-06-29
CN101437501B (zh) 2012-09-05
AU2007224250A1 (en) 2007-09-13
WO2007103134A3 (en) 2008-09-12
JP5722524B2 (ja) 2015-05-20
KR101650264B1 (ko) 2016-08-22
KR101527225B1 (ko) 2015-06-08
HK1120444A1 (en) 2009-04-03
RU2008139118A (ru) 2010-04-10
EP1988882A2 (en) 2008-11-12
IL193623A0 (en) 2009-08-03
DK1988882T3 (en) 2015-02-23
EP2918269A1 (en) 2015-09-16
US20100135992A1 (en) 2010-06-03
AU2007224250B2 (en) 2012-05-03
NZ570802A (en) 2012-03-30
JP2009528369A (ja) 2009-08-06
JP2013155202A (ja) 2013-08-15
HRP20150182T1 (hr) 2015-06-05
KR20140124023A (ko) 2014-10-23

Similar Documents

Publication Publication Date Title
RU2445975C2 (ru) Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
US20190309053A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
HK1120444B (en) Prolongation of survival of an allograft by inhibiting complement activity
AU2011236106A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
HK1157199A (en) Prolongation of survival of an allograft by inhibiting complement activity
HK1101962B (en) Prolongation of survival of an allograft by inhibiting complement activity

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190303